Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 2 (2007), Issue 8 (August)

1. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
   Transplantation, 84(2): 180-6. [Abstract] [Full-text]
2. Influence of donor histology on outcome in patients undergoing transplantation for hepatitis C.
   Transplantation, 84(2): 144-8. [Abstract] [Full-text]
3. Functionality of the immune system in patients with chronic hepatitis C: trial by superinfections and vaccinations.
   Expert Rev Vaccines, 6(4): 527-37. [Abstract] [Full-text]
4. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.
   Hepatology, 46(2): 590-7. [Abstract] [Full-text]
5. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study.
   Hepatology, 46(2): 380-7. [Abstract] [Full-text]
6. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.
   Hepatology, 46(2): 350-8. [Abstract] [Full-text]
7. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.
   Hepatology, 46(2): 324-9. [Abstract] [Full-text]
8. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C.
   Hepatology, 46(2): 315-23. [Abstract] [Full-text]
9. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy.
   Pediatrics, 120(2): e373-81. [Abstract] [Full-text]
10. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection.
    Hepatology, 46(2): 307-14. [Abstract] [Full-text]
11. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase.
    Hepatology, 46(2): 395-401. [Abstract] [Full-text]
12. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis.
    Hepatology, 46(2): 388-94. [Abstract] [Full-text]
13. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2.
    Hepatology, 46(2): 472-84. [Abstract] [Full-text]
14. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.
    Hepatology, 46(2): 371-9. [Abstract] [Full-text]
15. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution.
    Hepatology, 46(2): 339-49. [Abstract] [Full-text]
16. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C.
    Hepatology, 46(2): 297-306. [Abstract] [Full-text]
17. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.
    J Infect Dis, 196(5): 670-6. [Abstract] [Full-text]
18. Diammonium glycyrrhizinate, a component of traditional Chinese medicine Gan-Cao, prevents murine T-cell-mediated fulminant hepatitis in IL-10- and IL-6-dependent manners.
    Int Immunopharmacol, 7(10): 1292-8. [Abstract] [Full-text]
19. Efficient regulation of viral replication by siRNA in a non-human primate surrogate model for hepatitis C.
    Biochem Biophys Res Commun, 361(2): 294-300. [Abstract] [Full-text]
20. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
    Clin Infect Dis, 45(5): 624-32. [Abstract] [Full-text]
21. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
    Clin Infect Dis, 45(5): 618-23. [Abstract] [Full-text]
22. Twelve-week treatment of acute hepatitis C virus with pegylated interferon- alpha -2b in injection drug users.
    Clin Infect Dis, 45(5): 583-8. [Abstract] [Full-text]
23. Acute Q fever hepatitis in patients with and without underlying hepatitis B or C virus infection.
    Clin Infect Dis, 45(5): e52-9. [Abstract] [Full-text]
24. Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C.
    Transpl Int, 20(9): 771-8. [Abstract] [Full-text]
25. Development of specific antibodies to an ARF protein in treated patients with chronic HCV infection.
    Dig Dis Sci, 52(9): 2427-32. [Abstract] [Full-text]
26. Levels of hepatitis B virus (HBV) replication during the nonreplicative phase: HBV quantification by real-time PCR in Korea.
    Dig Dis Sci, 52(9): 2403-9. [Abstract] [Full-text]
27. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis.
    Dig Dis Sci, 52(9): 2433-7. [Abstract] [Full-text]
28. Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia.
    Dig Dis Sci, 52(9): 2410-7. [Abstract] [Full-text]
29. Factors influencing treatment efficacy of 24-week combination therapy with interferon alpha-2b plus ribavirin for chronic hepatitis C.
    Dig Dis Sci, 52(9): 2418-26. [Abstract] [Full-text]
30. Increased age, male gender, and cirrhosis, but not steatosis or a positive viral serology, negatively impact the life expectancy of patients who undergo liver biopsy.
    Dig Dis Sci, 52(9): 2276-81. [Abstract] [Full-text]
31. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.
    Gut, 56(9): 1296-301. [Abstract] [Full-text]
32. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model.
    Gut, 56(9): 1302-8. [Abstract] [Full-text]
33. The good and evil of flare: flares in hepatitis B virus chronic hepatitis.
    Eur J Gastroenterol Hepatol, 19(9): 821-3. [Abstract] [Full-text]
34. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Eur J Gastroenterol Hepatol, 19(9): 817-20. [Abstract] [Full-text]
35. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    Eur J Gastroenterol Hepatol, 19(9): 811-5. [Abstract] [Full-text]
36. Multiple primary liver lipomas in a patient with chronic hepatitis B: a case report.
    Eur J Gastroenterol Hepatol, 19(9): 807-9. [Abstract] [Full-text]
37. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone.
    Eur J Gastroenterol Hepatol, 19(9): 741-7. [Abstract] [Full-text]
38. The cost-effectiveness of the new protocol reflecting rapid virologic response to peginterferon alpha-2b and ribavirin for chronic hepatitis C.
    Eur J Gastroenterol Hepatol, 19(9): 733-9. [Abstract] [Full-text]
39. Increasing genetic diversity of hepatitis C virus in haemophiliacs with human immunodeficiency virus coinfection.
    J Gen Virol, 88: 2513-9. [Abstract] [Full-text]
40. Efficient infection of tree shrew (Tupaia belangeri) with hepatitis C virus grown in cell culture or from patient plasma.
    J Gen Virol, 88: 2504-12. [Abstract] [Full-text]
41. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.
    J Virol, 81(17): 9249-58. [Abstract] [Full-text]
42. Phenotypic and functional changes of cytotoxic CD56pos natural T cells determine outcome of acute hepatitis C virus infection.
    J Virol, 81(17): 9292-8. [Abstract] [Full-text]
43. Influences on hepatitis B virus replication by a naturally occurring mutation in the core gene.
    Virology, 365(2): 285-91. [Abstract] [Full-text]
44. High levels of subgenomic HCV plasma RNA in immunosilent infections.
    Virology, 365(2): 446-56. [Abstract] [Full-text]
45. Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose.
    Ann Emerg Med, 50(3): 292-313. [Abstract] [Full-text]
46. Comparative treatment of alpha-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model.
    Ann Emerg Med, 50(3): 282-8. [Abstract] [Full-text]
47. A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute acetaminophen poisoning.
    Ann Emerg Med, 50(3): 272-9. [Abstract] [Full-text]
48. Liver volume variation in patients with virus-induced cirrhosis: findings on MDCT.
    AJR Am J Roentgenol, 189(3): W153-9. [Abstract] [Full-text]
49. Cyclophilin inhibitors in hepatitis C viral infection.
    Expert Opin Investig Drugs, 16(9): 1345-54. [Abstract] [Full-text]
50. Effect of angiotensin AT1 receptor antagonist on D-galactosamine-induced acute liver injury.
    Clin Exp Pharmacol Physiol, 34(10): 985-91. [Abstract] [Full-text]
51. Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus.
    Transplantation, 84(4): 511-6. [Abstract] [Full-text]
52. Serum proteomics with SELDI-TOF-MS in congenital human cytomegalovirus hepatitis.
    J Med Virol, 79(10): 1500-5. [Abstract] [Full-text]
53. Molecular and cellular determinants of cell-to-cell transmission of HCV in vitro.
    J Med Virol, 79(10): 1491-9. [Abstract] [Full-text]
54. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    J Med Virol, 79(10): 1485-90. [Abstract] [Full-text]
55. Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine.
    J Med Virol, 79(10): 1472-7. [Abstract] [Full-text]
56. Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
    J Med Virol, 79(10): 1464-71. [Abstract] [Full-text]
57. Bile duct dysplasia in the setting of chronic hepatitis C and alcohol cirrhosis.
    Am J Surg Pathol, 31(9): 1410-3. [Abstract] [Full-text]
58. Epstein-Barr virus hepatitis: diagnostic value of in situ hybridization, polymerase chain reaction, and immunohistochemistry on liver biopsy from immunocompetent patients.
    Am J Surg Pathol, 31(9): 1403-9. [Abstract] [Full-text]
59. Hepatitic pattern of graft versus host disease in children.
    Pediatr Blood Cancer, 49(5): 727-30. [Abstract] [Full-text]
60. Elevated serum levels of interferon- gamma -inducible protein-10 in patients coinfected with hepatitis C virus and HIV.
    J Infect Dis, 196(7): 1053-7. [Abstract] [Full-text]
61. Risk of hepatocellular carcinoma and secondary structure of hepatitis C virus (HCV) NS3 protein amino-terminus, in patients infected with HCV subtype 1b.
    J Infect Dis, 196(7): 1006-9. [Abstract] [Full-text]
62. Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.
    Seizure, 16(7): 653-6. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.